Zhongao Bio-pharmaceutical Technology

Zhongao Bio-pharmaceutical Technology is a Chinese biotechnology company focused on the research and development of innovative treatments for metabolic diseases, particularly type 2 diabetes and obesity. Based in Guangzhou, the company leverages its expertise in medicinal chemistry and protein engineering to develop next-generation small molecules and peptide-based therapeutics. Their research efforts are primarily centered on well-validated metabolic pathways, including GLP-1 receptor agonism and DPP-4 inhibition. The company aims to provide high-quality, affordable therapeutic options for the growing population of patients with metabolic syndrome in China and globally.